Dr. Matthew Taylor, MD

Medical Oncology Portland, OR Male
NPI: 1134239197
Total Payments
$325,133
2024 Payments
$855.66
Companies
15
Transactions
252
Medicare Patients
588
Medicare Billing
$141,912

Payment Breakdown by Category

Other$164,793 (50.7%)
Consulting$126,100 (38.8%)
Travel$21,537 (6.6%)
Research$8,451 (2.6%)
Food & Beverage$4,252 (1.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $126,100 51 38.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $118,864 44 36.6%
Honoraria $45,929 19 14.1%
Travel and Lodging $21,537 74 6.6%
Unspecified $8,451 7 2.6%
Food and Beverage $4,252 57 1.3%

Payments by Type

General
$316,681
245 transactions
Research
$8,451
7 transactions

Top Paying Companies

Company Total Records Latest Year
E.R. Squibb & Sons, L.L.C. $104,706 85 $0 (2023)
EISAI INC. $102,316 78 $0 (2022)
Blueprint Medicines Corporation $45,972 37 $0 (2022)
Bayer HealthCare Pharmaceuticals Inc. $16,812 10 $0 (2020)
GENZYME CORPORATION $13,708 9 $0 (2021)
Merck Sharp & Dohme LLC $8,961 7 $0 (2022)
PFIZER INC. $8,040 6 $0 (2018)
F. Hoffmann-La Roche AG $5,791 6 $0 (2023)
Novartis Pharmaceuticals Corporation $5,001 2 $0 (2020)
ARRAY BIOPHARMA INC $4,375 2 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $855.66 4 Exelixis Inc. ($660.00)
2023 $17,589 12 E.R. Squibb & Sons, L.L.C. ($12,783)
2022 $68,319 56 EISAI INC. ($26,957)
2021 $64,551 44 Blueprint Medicines Corporation ($27,108)
2020 $38,780 21 Eisai Inc. ($20,569)
2019 $48,275 43 E.R. Squibb & Sons, L.L.C. ($23,446)
2018 $42,807 38 Eisai Inc. ($15,170)
2017 $43,956 34 E.R. Squibb & Sons, L.L.C. ($26,132)

All Payment Transactions

252 individual payment records from CMS Open Payments — Page 1 of 11

Date Company Product Nature Form Amount Type
12/17/2024 Regeneron Healthcare Solutions, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $16.80 General
Category: ONCOLOGY
07/29/2024 Regeneron Healthcare Solutions, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $20.70 General
Category: ONCOLOGY
05/16/2024 Boston Scientific Corporation — Food and Beverage In-kind items and services $158.16 General
04/25/2024 Exelixis Inc. CABOMETYX (Drug) Honoraria Cash or cash equivalent $660.00 General
Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC)
12/31/2023 F. Hoffmann-La Roche AG Gavreto (Drug) — In-kind items and services $3,219.34 Research
Study: Characteristics and survival outcomes of patients with metastatic RET fusion-positive solid tumors receiving non-RET inhibitor standards of care in a real-world setting • Category: BioOncology
12/31/2023 F. Hoffmann-La Roche AG Gavreto (Drug) — In-kind items and services $1,550.50 Research
Study: BLU667 1101 ARROW ongoing • Category: BioOncology
12/01/2023 Regeneron Healthcare Solutions, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $16.80 General
Category: ONCOLOGY
08/22/2023 Regeneron Healthcare Solutions, Inc. LIBTAYO (Biological) Food and Beverage In-kind items and services $19.80 General
Category: ONCOLOGY
03/22/2023 E.R. Squibb & Sons, L.L.C. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $7,623.00 General
03/22/2023 E.R. Squibb & Sons, L.L.C. — Travel and Lodging Cash or cash equivalent $44.34 General
03/22/2023 E.R. Squibb & Sons, L.L.C. — Travel and Lodging Cash or cash equivalent $24.00 General
03/09/2023 E.R. Squibb & Sons, L.L.C. — Travel and Lodging Cash or cash equivalent $408.64 General
03/09/2023 E.R. Squibb & Sons, L.L.C. — Travel and Lodging Cash or cash equivalent $143.60 General
03/09/2023 E.R. Squibb & Sons, L.L.C. — Food and Beverage Cash or cash equivalent $88.20 General
01/18/2023 E.R. Squibb & Sons, L.L.C. — Travel and Lodging Cash or cash equivalent $141.25 General
01/04/2023 E.R. Squibb & Sons, L.L.C. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,310.00 General
12/16/2022 EISAI INC. Lenvima (Drug) Consulting Fee Cash or cash equivalent $680.00 General
Category: Oncology
12/15/2022 E.R. Squibb & Sons, L.L.C. — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,310.00 General
12/15/2022 E.R. Squibb & Sons, L.L.C. — Food and Beverage Cash or cash equivalent $125.00 General
12/08/2022 EISAI INC. Lenvima (Drug) Consulting Fee Cash or cash equivalent $1,700.00 General
Category: Oncology
12/08/2022 EISAI INC. Lenvima (Drug) Food and Beverage Cash or cash equivalent $118.29 General
Category: Oncology
12/08/2022 EISAI INC. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $73.63 General
Category: Oncology
12/08/2022 EISAI INC. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $24.00 General
Category: Oncology
12/03/2022 Merck Sharp & Dohme LLC KEYTRUDA (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,270.00 General
Category: ONCOLOGY
11/28/2022 Merck Sharp & Dohme LLC KEYTRUDA (Biological) Travel and Lodging Cash or cash equivalent $25.00 General
Category: ONCOLOGY
123…11»

Research Studies & Clinical Trials

Study Name Company Amount Records
Characteristics and survival outcomes of patients with metastatic RET fusion-positive solid tumors receiving non-RET inhibitor standards of care in a real-world setting F. Hoffmann-La Roche AG $3,219 1
RESEARCH RELATED PUBLICATIONS SUPPORT Novartis Pharmaceuticals Corporation $2,813 1
BLU667 1101 ARROW ongoing F. Hoffmann-La Roche AG $1,551 1
STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 F. Hoffmann-La Roche AG $562.92 1
A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult F. Hoffmann-La Roche AG $142.87 1
A Phase I IIa Trial With BMS 986158 a Small Molecule Inhibitor of the Bromodomain and Extra Terminal BET Proteins in Subjects with Selected Advanced Solid Tumors E.R. Squibb & Sons, L.L.C. $90.00 1
A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS, AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT P F. Hoffmann-La Roche AG $72.62 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 156 409 $167,958 $38,187
2022 3 155 464 $192,522 $44,645
2021 4 132 413 $151,930 $36,161
2020 5 145 314 $91,975 $22,919
Total Patients
588
Total Services
1,600
Medicare Billing
$141,912
Procedure Codes
17

All Medicare Procedures & Services

17 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 49 206 $98,468 $22,790 23.1%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 70 164 $53,300 $11,478 21.5%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2023 15 15 $6,675 $1,627 24.4%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 11 11 $6,655 $1,621 24.4%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 11 13 $2,860 $671.58 23.5%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 56 232 $111,360 $26,419 23.7%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 77 210 $67,830 $15,047 22.2%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 22 22 $13,332 $3,179 23.8%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 65 240 $78,000 $18,866 24.2%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 39 97 $46,851 $10,700 22.8%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2021 13 61 $20,374 $5,044 24.8%
99204 New patient outpatient visit, total time 45-59 minutes Facility 2021 15 15 $6,705 $1,551 23.1%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 65 187 $47,124 $11,779 25.0%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 39 68 $24,208 $6,295 26.0%
99205 New patient office or other outpatient visit, typically 60 minutes Facility 2020 15 15 $8,100 $1,877 23.2%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 13 31 $7,161 $1,866 26.1%
99204 New patient office or other outpatient visit, typically 45 minutes Facility 2020 13 13 $5,382 $1,101 20.5%

About Dr. Matthew Taylor, MD

Dr. Matthew Taylor, MD is a Medical Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1134239197.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Taylor, MD has received a total of $325,133 in payments from pharmaceutical and medical device companies, with $855.66 received in 2024. These payments were reported across 252 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($126,100).

As a Medicare-enrolled provider, Taylor has provided services to 588 Medicare beneficiaries, totaling 1,600 services with total Medicare billing of $141,912. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.

Practice Information

  • Specialty Medical Oncology
  • Location Portland, OR
  • Active Since 08/30/2006
  • Last Updated 02/16/2021
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1134239197

Products in Payments

  • Lenvima (Drug) $102,213
  • GAVRETO (Drug) $41,576
  • Non-Covered $11,012
  • KEYTRUDA (Biological) $8,961
  • OPDIVO (Biological) $8,737
  • XALKORI (Drug) $8,040
  • LIBTAYO (Biological) $7,964
  • LIBTAYO (Drug) $7,539
  • Vitrakvi (Drug) $5,800
  • Gavreto (Drug) $4,770
  • BRAFTOVI (Drug) $4,375
  • DOVITINIB LACTATE (Drug) $2,813
  • CABOMETYX (Drug) $2,310
  • MEKINIST (Drug) $2,188
  • Cabometyx (Drug) $1,650
  • CAPRELSA (Drug) $899.10
  • ROZLYTREK (Biological) $705.79
  • Non-Covered Product (Drug) $242.71
  • None (Drug) $42.72

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Portland

David Page, M.d, M.D

Medical Oncology — Payments: $236,791

Medical Oncology $236,791

Tomasz Beer, Md, MD

Medical Oncology — Payments: $179,452

Medical Oncology $179,452

Alison Conlin, Md, MD

Medical Oncology — Payments: $86,283

Medical Oncology $86,283

Brendan Curti, Md, MD

Medical Oncology — Payments: $66,023

Medical Oncology $66,023

Christopher Ryan, Md, MD

Medical Oncology — Payments: $52,261

Medical Oncology $52,261

Dr. Jason Taylor, Md, Phd, MD, PHD

Medical Oncology — Payments: $42,506

Medical Oncology $42,506